How PhD was paid
$951,343 in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Options | Other | Total |
|---|---|---|---|---|---|
| Spyros Papapetropoulos, M.D., PhDPresident and Chief Executive Officer | $550,000 | $226,875 | $123,660 | $50,808 | $951,343 |
| Tim CunninghamChief Financial Officer | — | — | — | — | $254,363 |
What changed and why
- $951K$951,343 was the CEO’s total compensation in 2025, versus $751,875 in 2024.
- $124K$123,660 of the CEO’s 2025 compensation was option awards.
- $227K$226,875 was the CEO’s 2025 bonus.
- $50,808$50,808 was reported as the CEO’s other compensation in 2025.
- $254K$254,363 was the CFO’s reported total compensation in 2025.
Other Neuphoria Therapeutics proxy statements
- 2026 proxy statement
Spyros Papapetropoulos, MD. paid $1.7M (+81% on the year).
Filed Sep 18, 2026
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.